An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care

References

• Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347–82
   PubMed Web of Science ®Google Scholar
• Barlett JG, Mundy LM. Community-acquired pneumonia. New Eng J Med 1995;333:1618–24
   PubMed Web of Science ®Google Scholar
• Elixahauser A, Duffy SQ, Sommer JP. Most frequent diagnoses and procedures for DRGs by insurance status. AHCPR publication No. 97–0006. Healthcare cost and utilization project, HCUP-3. Research note 4. Rockville (MD): Agency for Health Care Policy and Research, 1996
   Google Scholar
• Bernstein JM, Campbell GD. Treatment of pneumonia and its implications for antimicrobial resistance. Chest 1999;1158:15–25
   Google Scholar
• Rittenhouse BE, Stinnett AA, Dulisse B, et al. Evaluating the costs of levofloxacin and ceftriaxone in inpatient adults with community-acquired pneumonia. P & T 1999;24:169–79
   Google Scholar
• Minino AM, Arias E, Kochanek KD, Murphy SL, Smith BL. Deaths: final data for 2000. Natl Vital Stat Rep 2002;50: 1–119
   Google Scholar
• Marston BJ, Plouffe JF, File TM, et al. Incidence of community-acquired pneumonia requiring hospitalizations: results of a population-based active surveillance study in Ohio. [Community-Based Pneumonia Incidence Group]. Arch Intern Med 1997;157:1709–18
   PubMed Web of Science ®Google Scholar
• Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. J Am Med Assoc 1996;275:134–41
   PubMed Web of Science ®Google Scholar
• Marr JJ, Moffet HL, Kunin CM. Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the Infectious Disease Society of America. J Infect Dis 1988;157:869–786
   Google Scholar
• Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820–37
   Google Scholar
• Angus DC, Marrie TJ, Obrovsky DS, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med 2002;166:717–23
   PubMed Web of Science ®Google Scholar
• Niederman MS, Peters SP. Update in pulmonary medicine. Ann Intern Med 1998;128:208–15
   PubMed Web of Science ®Google Scholar
• Dixon RE. Economic costs of respiratory tract infections in the United States. Am J Med 1985;78(S):52–7
   Google Scholar
• Marrie TJ. Community-acquired pneumonia: epidemiology, etiology and treatment. Infect Dis Clin North Am 1998;12:723–40
   PubMed Web of Science ®Google Scholar
• Barlett JG, Breiman RF, Mandell LA, et al., for the Infectious Diseases Society of America. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998;26:811–38
   PubMed Web of Science ®Google Scholar
• Nicolau DP, Gleason PP, Destache CJ, White RL. Panel discussion: maximizing outcomes in respiratory tract infections in the age of resistance. Pharmacotherapy 2002;22(S):30–2
   Google Scholar
• Mandell LA, Bartlett JG, Dowell SF, File Jr TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired Pneumonia in Immunocompetent Adults: IDSA Guidelines. Clin Infect Dis 2003;37:1405–33
   PubMed Web of Science ®Google Scholar
• ATS Board of Directors. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001;163:1730–54
   PubMedGoogle Scholar
• Gleason PP, Kapoor WN, Stone RA, et al. Medical outcomes and antimicrobial costs with the use of American Thoracic Society guidelines for outpatients in community-acquired pneumonia. J Am Med Assoc 1997;278:32–9
   PubMed Web of Science ®Google Scholar
• Heffelfinger JF, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399–408
   PubMed Web of Science ®Google Scholar
• File Jr TM, Tan JS. International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides. Drugs 2003;63:181–205
   PubMed Web of Science ®Google Scholar
• Jones RN, Mandell LA. Fluoroquinolones for the treatment of outpatient community-acquired pneumonia. Diag Micro Infect Dis 2002;44:69–76
   PubMed Web of Science ®Google Scholar
• Hospital and Payer ICD-9-CM, vols 1, 2, and 3. Salt Lake City (Utah): Medicode; 2001
   Google Scholar
• Clark DO, Von Korff M, Saunders K, et al. A chronic disease score with empirically derived weights. Med Care 1995;33:783–95
   PubMed Web of Science ®Google Scholar
• Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992;15:77–83
   PubMed Web of Science ®Google Scholar
• Chen DK, McGreer A, de Azavedo JC, et al. Decreased suscept ibility of Streptococcus pneumoniae to fluoroquinolones in Canada. New Engl J Med 1999;341:233–9
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences, 2nd ed. Hillsdale (NJ): Lawrence-Erlbaum Associates; 1988
   Google Scholar
• Cohen J. A power primer. Psychol Bull 1992;122:155–9
   Web of Science ®Google Scholar
• Clark DO, Von Korff M, Saunders K, et al. A chronic disease score with empirically derived weights. Med Care 1995;33:783–95
   PubMed Web of Science ®Google Scholar
• Blasi F, Tarsia P, Cosentini R, Cazzola M, Allegra L. Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections. Expert Opinion Investig Drugs 2003;12:1165–77
   Google Scholar
• Martin SJ, Sahloff EG, Close SJ. Evaluation and cost assessment of fluoroquinolones in community-acquired respiratory infections. Expert Opinion Pharmacother 2002;3:1251–66
   Google Scholar
• Hurst M, Lamb HM, Scott LJ, Figgitt DP. Levofloxacin: an updated review of its use in the treatment of bacterial infections. Drugs 2002;62:2127–67
   PubMed Web of Science ®Google Scholar
• Mommeja-Martin H, Carbon C. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections? Drugs 1999;57:851–3
   Google Scholar
• Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. New Eng J Med 2004;351:1089–96
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New Engl J Med 1997;336:243–50
   PubMed Web of Science ®Google Scholar
• Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. Pharmacoeconomics 2002;20:513–28
   Google Scholar
• Richerson MA, Ambrose PG, Quintiliani R, et al. Pharmaco-economic evaluation of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia. Infect Dis Clin Pract 1998;7:227–33
   Web of Science ®Google Scholar
• Quintiliani R, Cooper BW, Briceland LL, et al. Economic impact of streamlining antibiotic administration. Am J Med 1987;82(S):391–4
   Google Scholar
• Quintiliani R. Strategies for the cost-effective use of antibiotics in infectious diseases, 2nd ed. Philadelphia (PA): WB Saunders Co.; 1998. p.412–22
   Google Scholar
• Briceland LL, Nightingale CH, Quintiliani R, et al. Antibiotic streamlining from combination therapy to monotherapy utilizing an interdisciplinary approach. Arch Intern Med 1988;148:2019–22
   PubMed Web of Science ®Google Scholar
• Marrie TJ. Empiric treatment of ambulatory community-acquired pneumonia: always include treatment for atypical agents. Infec Dis Clin North Am 2004;18:829–41
   PubMed Web of Science ®Google Scholar